Top

Published in:

01-02-2021 | Systemic Lupus Erythematosus | Original Communication

Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis

Authors: Lara Marie Pangan Lo, Bruce V. Taylor, Tania Winzenberg, Andrew J. Palmer, Leigh Blizzard, Hasnat Ahmad, Mohammad Akhtar Hussain, Ingrid van der Mei

Published in: Journal of Neurology | Issue 2/2021

Abstract

Background

Little is known about the relative contribution of comorbidities in predicting the health-related quality of life (HRQoL) of people with Multiple Sclerosis (PwMS).

Objective

To determine the associations between the number of and individual comorbidities and HRQoL and estimate the relative contribution of different comorbidities on HRQoL.

Methods

Cross-sectional analysis of data on self-reported presence of 30 comorbidities and HRQoL from the Australian MS Longitudinal Study (AMSLS) participants (n = 902). HRQoL was measured using the Assessment of Quality of Life-8 Dimensions (AQoL-8D). Linear regression and general dominance analysis were used.

Results

Higher number of comorbidities was associated with lower HRQoL (p trend p < 0.01). Comorbidities accounted for 18.1% of the variance in HRQoL. Mental health and musculoskeletal disorders were the strongest contributors to lower HRQoL. Of individual comorbidities, systemic lupus erythematosus (SLE) [β = − 0.16 (− 0.27, − 0.05)] and depression [β = − 0.15(− 0.18, − 0.13)] were most strongly associated with overall HRQoL, depression [β = − 0.14(− 0.16, − 0.11)] and anxiety [β = − 0.10 (− 0.13, − 0.07)] with psychosocial HRQoL, and SLE [β = − 0.18 (− 0.29, − 0.07)], rheumatoid arthritis [β = − 0.11 (− 0.19, − 0.02)] and hyperthyroidism [β = − 0.11 (− 0.19, − 0.03)) with physical HRQoL.

Conclusion

Comorbidities potentially make important contributions to HRQoL in PwMS. Our findings highlight groups of and individual comorbidities that could provide the largest benefits for the HRQoL of PwMS if they were targeted for prevention, early detection, and optimal treatment.

Available only for authorised users

World Health Organization (1997) WHOQOL: measuring quality of life. https://www.who.int/healthinfo/survey/whoqol-qualityoflife/en/. Accessed 12 June 2018

MS International Federation What influences quality of life with MS and how can we improve it? MS International Federation. https://www.msif.org/living-with-ms/what-influences-quality-of-life/. Accessed 27 June 2018

Nortvedt MW, Riise T, Myhr KM, Nyland HI (1999) Quality of life in multiple sclerosis: Measuring the disease effects more broadly. Neurology 53(5):1098–1103CrossRef

Warren SA, Turpin KVL, Pohar SL, Jones CA, Warren KG (2009) Comorbidity and health-related quality of life in people with multiple sclerosis. Int J MS Care 11(1):6–16CrossRef

Janzen W, Turpin KVL, Warren SA, Marrie RA, Warren KG (2013) Change in the health-related quality of life of multiple sclerosis patients over 5 years. Int J MS Care 15(1):46–53CrossRef

Ahmad H, Taylor BV, Ivd M, Colman S, O'Leary BA, Breslin M, Palmer AJ (2017) The impact of multiple sclerosis severity on health state utility values: evidence from Australia. Mult Scler J 23(8):1157–1166CrossRef

Marrie RA, Horwitz R, Cutter G, Tyry T (2012) Cumulative impact of comorbidity on quality of life in MS. Acta Neurol Scand 125(3):180–186. https://doi.org/10.1111/j.1600-0404.2011.01526.xCrossRefPubMed

Hermann BP, Vickrey B, Hays RD, Cramer J, Devinsky O, Meador K, Perrine K, Myers LW, Ellison GW (1996) A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 25(2):113–118CrossRef

Berrigan LI, Fisk JD, Patten SB, Tremlett H, Wolfson C, Warren S, Fiest KM, McKay KA, Marrie RA, For the CIHR Team in the Epidemiology Impact of Comorbidity on Multiple Sclerosis (ECoMS) (2016) Health-related quality of life in multiple sclerosis: Direct and indirect effects of comorbidity. Neurology 86(15):1417–1424. https://doi.org/10.1212/WNL.0000000000002564CrossRefPubMedPubMedCentral

10.

Turpin KVL, Carroll LJ, Cassidy JD, Hader WJ (2007) Deterioration in the health-related quality of life of persons with multiple sclerosis: the possible warning signs. Mult Scler J 13(8):1038–1045CrossRef

11.

Weiland TJ, De Livera AM, Brown CR, Jelinek GA, Aitken Z, Simpson SL, Neate SL, Taylor KL, O'Kearney E, Bevens W, Marck CH (2018) Health outcomes and lifestyle in a sample of people with multiple sclerosis (HOLISM): longitudinal and validation cohorts. Front Neuro. https://doi.org/10.3389/fneur.2018.01074CrossRef

12.

Taylor BV, Palmer A, Simpson S Jr, Lucas R, Group NS, Simmons RD, Mason D, Pearson J, Clarke G, Sabel C, Willoughby E, Richardson A, Abernethy D (2013) Assessing possible selection bias in a national voluntary MS longitudinal study in Australia. Mult Scler J 19(12):1627–1631. https://doi.org/10.1177/1352458513481511CrossRef

13.

Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. https://doi.org/10.1002/ana.22366CrossRefPubMedPubMedCentral

14.

McDonald WI, Compston A, Edan G, Goodkin D, Hartung H-P, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, Svd N, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 50(1):121–127. https://doi.org/10.1002/ana.1032CrossRefPubMed

15.

Marrie RA, Cohen J, Stuve O, Trojano M, Sorensen PS, Reingold S, Cutter G, Reider N (2015) A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. Mult Scler J 21(3):263–281. https://doi.org/10.1177/1352458514564491CrossRef

16.

Kang JH, Chen YH, Lin HC (2010) Comorbidities amongst patients with multiple sclerosis: a population-based controlled study. Eur J Neurol 17(9):1215–1219. https://doi.org/10.1111/j.1468-1331.2010.02971.xCrossRefPubMed

17.

Marrie R, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T (2008) Comorbidity, socioeconomic status and multiple sclerosis. Mult Scler 14:1091–1098. https://doi.org/10.1177/1352458508092263CrossRefPubMed

18.

Richardson J, Sinha K, Iezzi A, Khan MA (2014) Modelling utility weights for the Assessment of Quality of Life (AQoL)-8D. Qual Life Res 23(8):2395–2404CrossRef

19.

Campbell JA, Hensher M, Neil A, Venn A, Otahal P, Wilkinson S, Palmer AJ (2018) An exploratory study: a head-to-head comparison of the EQ-5D-5L and AQoL-8D for long-term publicly waitlisted bariatric surgery patients before and 3 months after bariatric surgery. Pharmacoecon Open 2(4):443–458CrossRef

20.

Richardson J, Iezzi A, Khan MA, Maxwell A (2014) Validity and reliability of the assessment of quality of life (AQoL)-8D multi-attribute utility instrument. Patient 7(1):85–96CrossRef

21.

Luchman JN (2013) DOMIN: Stata module to conduct dominance analysis. https://ideas.repec.org/c/boc/bocode/s457629.html. Accessed 16 Apr 2018

22.

Nathans LL, Oswald FL, Nimon K (2012) Interpreting multiple linear regression: a guidebook of variable importance. Pract Assess Rese Eval 17(9):1–19

23.

Azen R, Budescu D (2003) The dominance analysis approach for comparing predictors in multiple regression. Psychol Methods 8:129–148CrossRef

24.

Azen R, Traxel N (2009) Using dominance analysis to determine predictor importance in logistic regression. J Educ Behav Stat 34:319–347CrossRef

25.

Greenland S (1989) Modeling and variable selection in epidemiologic analysis. Am J Public Health 79(3):340–349CrossRef

26.

Kamangar F (2012) Confounding variables in epidemiologic studies: basics and beyond. Arch Iran Med 15:508–516PubMed

27.

Maxwell A, Özmen M, Iezzi A, Richardson J (2016) Deriving population norms for the AQoL-6D and AQoL-8D multi-attribute utility instruments from web-based data. Qual Life Res 25(12):3209–3219CrossRef

28.

Lo LMP, Taylor BV, Winzenberg T, Palmer A, Blizzard L, van der Mei I (2020) Comorbidities contribute substantially to the severity of common multiple sclerosis symptoms. J Neurol (Accepted)

29.

Marrie RA (2018) Comorbidities in multiple sclerosis: a clinical resource guide. The Consortium of Multiple Sclerosis Centers (CMSC); Nurse Practitioner Alternatives (NPA); Catamount Medical Education. https://mscomorbidities.com/. Accessed 30 Mar 2018

30.

Marrie RA, Patten SB, Tremlett H, Wolfson C, Warren S, Svenson LW, Jette N, Fisk J, Epidemiology CTit, Impact of Comorbidity on Multiple S, (2016) Sex differences in comorbidity at diagnosis of multiple sclerosis: A population-based study. Neurology 86(14):1279–1286. https://doi.org/10.1212/WNL.0000000000002481CrossRefPubMedPubMedCentral

31.

Marrie RA, Horwitz R, Cutter G, Tyry T, Campagnolo D, Vollmer T (2009) The burden of mental comorbidity in multiple sclerosis: frequent, underdiagnosed, and undertreated. Mult Scler J 15(3):385–392CrossRef

32.

Woolf AD, Pfleger B (2003) Burden of major musculoskeletal conditions. Bull World Health Organ 81(9):646–656PubMedPubMedCentral

33.

Aitken D, Jones G, Winzenberg T (2019) Clinical overview of osteoarthritis (OA) and the challenges faced for future management. In. doi: 10.1016/B978–0–12–801238–3.11419–9

34.

Degenhardt A, Ramagopalan SV, Scalfari A, Ebers GC (2009) Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol 5(12):672–682CrossRef

Title: Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis
Authors: Lara Marie Pangan Lo
Bruce V. Taylor
Tania Winzenberg
Andrew J. Palmer
Leigh Blizzard
Hasnat Ahmad
Mohammad Akhtar Hussain
Ingrid van der Mei
Publication date: 01-02-2021
Publisher: Springer Berlin Heidelberg
Keywords: Systemic Lupus Erythematosus
Multiple Sclerosis
Rheumatoid Arthritis
Published in: Journal of Neurology / Issue 2/2021
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-020-10195-w

At a glance: The STEP trials

Springer Medicine

Estimating the relative contribution of comorbidities in predicting health-related quality of life of people with multiple sclerosis

Abstract

Background

Objective

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Objective

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2021

Correction to: Refractory anti‑NMDAR encephalitis successfully treated with bortezomib and associated movements disorders controlled with tramadol: a case report with literature review

Associated co-morbidities in a retrospective cohort of orthostatic tremor

Dissociation of caloric and head impulse tests: a marker of Meniere's disease

Correction to: Utility of the Parkinson’s disease-Cognitive Rating Scale for the screening of global cognitive status in Huntington’s disease

Deep geno- and phenotyping in two consanguineous families with CMT2 reveals HADHA as an unusual disease-causing gene and an intronic variant in GDAP1 as an unusual mutation

Parkinson’s disease laterality: a 11C-PE2I PET imaging study